Compare Sana Biotechnology Inc (SANA) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while YieldMax TSLA Option Income Strategy ETF trades at $25.63. The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| SANA | TSLY | |
|---|---|---|
Market Cap | $873.84M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $5.92 | $48.25 |
52-Week Low | $2.68 | $25.07 |
Enterprise Value | $848.03M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
TSLY trades at $25.07, down 2.57% over the past day, with a bearish technical outlook from moving averages and oscillators. The ETF maintains a high distribution yield, with weekly dividends averaging around $0.30 per share, though recent news highlights concerns about capped upside relative to Tesla's performance. Key support sits near $25, while resistance is at $26.
The outlook for TSLY is cautious due to its option income strategy limiting capital appreciation. Risks include volatility from Tesla's stock movements and potential erosion of principal from return of capital distributions. Investors seeking high yield may find value, but must weigh the trade-off between income and growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
